Literature DB >> 7241890

Glucose absorption during continuous ambulatory peritoneal dialysis.

G P Grodstein, M J Blumenkrantz, J D Kopple, J K Moran, J W Coburn.   

Abstract

Patients undergoing continuous ambulatory peritoneal dialysis (CAPD) are exposed to a continuous infusion of glucose via their peritoneal cavity. We performed studies to quantitate the amount of energy derived from dialysate glucose. Net glucose absorption averaged 182 +/- (SD) 61 g/day in 19 studies with a dialysate dextrose concentration of 1.5 or 4.25 g/dl. The amount of glucose absorbed per liter of dialysate (y) varied with the concentration of glucose in dialysate (x), (y = 11.3x - 10.9, r = 0.96). The amount of glucose absorbed per day during a given dialysis regimen was constant. Energy intake from dialysate glucose was 8.4 +/- 2.8 kcal/kg of body wt per day, or 12 to 34% of total energy intake. This additional energy may contribute to the anabolic effect reported during CAPD. The ability to vary glucose absorption by altering the dialysate glucose concentration may prove a useful tool to modify energy intake.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7241890     DOI: 10.1038/ki.1981.53

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  25 in total

1.  Dietary energy requirements in relatively healthy maintenance hemodialysis patients estimated from long-term metabolic studies.

Authors:  Anuja Shah; Rachelle Bross; Bryan B Shapiro; Gillian Morrison; Joel D Kopple
Journal:  Am J Clin Nutr       Date:  2016-02-10       Impact factor: 7.045

Review 2.  Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes?

Authors:  Murali Krishnan; Paul Tam; George Wu; Andrzej Breborowicz; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 3.  Symptom Management of the Patient with CKD: The Role of Dialysis.

Authors:  Valerie Jorge Cabrera; Joni Hansson; Alan S Kliger; Fredric O Finkelstein
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 8.237

Review 4.  Nutritional management in the critically ill child with acute kidney injury: a review.

Authors:  Sidharth Kumar Sethi; Norma Maxvold; Timothy Bunchman; Pranaw Jha; Vijay Kher; Rupesh Raina
Journal:  Pediatr Nephrol       Date:  2016-06-20       Impact factor: 3.714

5.  Some hormones, minerals and vitamin D in continuous ambulatory peritoneal dialysis.

Authors:  L Janicka; A Ksiazek; Z Twardowski; F Kokot
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

6.  Self-Reported Interview-Assisted Diet Records Underreport Energy Intake in Maintenance Hemodialysis Patients.

Authors:  Bryan B Shapiro; Rachelle Bross; Gillian Morrison; Kamyar Kalantar-Zadeh; Joel D Kopple
Journal:  J Ren Nutr       Date:  2015-02-11       Impact factor: 3.655

Review 7.  Updates on the management of diabetes in dialysis patients.

Authors:  Connie M Rhee; Angela M Leung; Csaba P Kovesdy; Katherine E Lynch; Gregory A Brent; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2014-03       Impact factor: 3.455

8.  High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients.

Authors:  Yueqiang Wen; Qunying Guo; Xiao Yang; Xianfeng Wu; Shaozhen Feng; Jiaqing Tan; Ricong Xu; Xueqing Yu
Journal:  Perit Dial Int       Date:  2013-12-01       Impact factor: 1.756

9.  The effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patients.

Authors:  Kyu-Hyang Cho; Jun-Young Do; Jong-Won Park; Kyung-Woo Yoon; Yong-Lim Kim
Journal:  Perit Dial Int       Date:  2013-01-02       Impact factor: 1.756

Review 10.  Dialysis and pediatric acute kidney injury: choice of renal support modality.

Authors:  Scott Walters; Craig Porter; Patrick D Brophy
Journal:  Pediatr Nephrol       Date:  2008-05-16       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.